Organ transplants, including liver, heart, kidney, lung and pancreas, are now a routine procedure in many parts of the world. The outcomes of these transplants have improved with the refinement of the procedures but autoimmune rejection of organ transplants remains a major problem. T-lymphocytes play a key role in the immune response but current t-cell inhibiting drugs are toxic, limiting their use.
Researchers at the University of California, Davis, have developed a method compromising of triarylmethane compounds for the immunosuppressive treatment of autoimmune disorders, graft rejection, and graft or host disease. This method utilizes therapeutically effective amounts of certain substituted triarylmethane compounds administered to patients. This results in selectively inhibited lymphocytes without concomitant inhibition of P450-dependent enzyme systems. Thus, an immunosuppressive and anti-inflammatory response can be created while bypassing the usual problem of organ/graft rejection and graft or host disease associated with transplants.
Researchers at the University of California, Davis, have developed a method for preparing therapeutically effective amounts of triarylmethane compounds for immunosuppressive treatment of autoimmune disorders, graft rejection, and graft or host disease.
Immunosuppressive treatment of autoimmune disorders
Creates an anti-inflammatory responseMinimizes organ/graft rejection and graft or host disease
|United States Of America||Issued Patent||7,235,577||06/26/2007||2000-074|
T-lymphocyte, triarylmethane compounds, immunosuppressive, organ transplants, graft rejection, autoimmune, anti-inflammatory